Research Papers:

Immune activity and biodistribution of polypeptide K237 and folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles radiolabeled with 99mTc

Zelai He, Xiangyu Zhang, Jingwen Huang, Yufeng Wu, Xuanzhang Huang, Jie Chen, Junyong Xia, Hao Jiang, Jing Ma and Jian Wu _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:76635-76646. https://doi.org/10.18632/oncotarget.12850

Metrics: PDF 2683 views  |   HTML 2932 views  |   ?  


Zelai He1,3,*, Xiangyu Zhang4,*, Jingwen Huang1,3,*, Yufeng Wu 5, Xuanzhang Huang1, Jie Chen1, Junyong Xia6, Hao Jiang3, Jing Ma2, Jian Wu1

1The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China

2Ultrasonic Department, Shanghai Songjiang Center Hospital, Shanghai, China

3The First Affiliated Hospital of Bengbu Medical College, Bengbu, China

4Department of Pathology, Jining No.1 Peoples’ Hospital, Jining, China

5Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

6Department of Nuclear Medicine, The Affiliated Provincial Hospital of Anhui Medical University, Hefei, China

*These authors contributed equally to this work

Correspondence to:

Junyong Xia, email: [email protected]

Hao Jiang, email: [email protected]

Jing Ma, email: [email protected]

Jian Wu, email: [email protected]

Keywords: K237, folate, PEG-PLGA, nanoparticles, biodistribution

Received: July 29, 2016     Accepted: October 12, 2016     Published: October 24, 2016


In a previous study, amphiphilic copolymer, polypeptide K237 (HTMYYHHYQHHL) and folic acid (FA) modified poly(ethylene glycol)-poly(lactic-co-glycolic acid) (K237/FA-PEG-PLGA) nanoparticles were developed and studied as a drug carrier. To further promote the clinical application of K237/FA-PEG-PLGA nanoparticles and provide guidance for future research, we need to examine their specific biodistribution in vivo. In this study, K237/FA-PEG-PLGA nanoparticles were effectively labeled by a direct method with Technetium-99m (99mTc) using stannous chloride as a reducing agent. The optimal stability of the labeled nanoparticles was determined by evaluating their radiochemical purity in serum, physiological saline, diethylenetriaminepentaacetic acid (DTPA) and cysteine solutions. The affinity of ligands and receptors was elicited by cell binding and blocking experiments in KDR/folate receptor high expressing SKOV-3 ovarian cancer cells. The nanoparticles biodistribution was studied after intravenous administration in healthy mice xenografted with SKOV-3 cells. A higher percent injected dose per gram of tissue (% ID/g) was observed in liver, kidney, spleen, blood and tumor at 3 and 9 h post-injection. Scintigraphic images revealed that the radioactivity was mainly concentrated in tumor, liver, kidney and bladder; and in the heart, lung, and muscle was significantly lower at 3 h. The radioactivity distribution in the images is consistent with the in vivo biodistribution data. Our works demonstrated that K237/FA-PEG-PLGA nanoparticles have great potential as biodegradable drug carriers, especially for tumors expressing the folate and KDr receptor.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12850